Compugen Ltd. logo
Compugen Ltd. CGEN
$ 2.22 22.38%

Annual report 2024
added 02-21-2026

report update icon

Compugen Ltd. Financial Statements 2011-2026 | CGEN

Annual Financial Statements Compugen Ltd.

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

148 M 262 M 88.3 M 299 M 968 M 458 M 191 M 154 M 234 M 238 M 371 M 425 M 192 M 181 M

Shares

89.5 M 87.6 M 86.6 M 84.2 M 79.6 M 63.6 M 55.3 M 51.2 M 50.9 M 50.4 M 47.8 M 38.9 M 35.8 M 34.3 M

Historical Prices

1.65 2.99 1.02 3.55 12.2 7.2 3.45 3 4.75 4.71 7.76 10.8 5.42 5.35

Net Income

-14.2 M -18.8 M -33.7 M -34.2 M -29.7 M -27.3 M -22.6 M -37.1 M -31.5 M -20.2 M -11.1 M -14.1 M -13.6 M -12 M

Revenue

- - - 6 M 2 M - 17.8 M - 712 K 9.28 M 12.4 M 3.55 M 240 K -

Cost of Revenue

7.93 M 2 M 975 K 680 K 60 K - 1.03 M - 223 K 1.63 M 3.34 M 2.51 M 201 K -

Gross Profit

19.9 M 31.5 M 6.52 M 5.32 M 1.94 M - 16.8 M - 489 K 7.64 M 9.02 M 1.04 M 40 K -

Operating Income

-14.9 M -13 M -35.4 M -35.1 M -31.5 M -28.9 M -23.2 M -37.4 M -32.6 M -20.9 M -12.3 M -17 M -13.5 M -12 M

Interest Expense

- - - - - - - - - - - - - 281 K

EBITDA

- - - -34.6 M -30.8 M -27.9 M -21.8 M -35.8 M -31.1 M -19.8 M -11.7 M -16.7 M -13.2 M -11.8 M

Operating Expenses

- - - 40.4 M 33.4 M 28.9 M 40 M 37.4 M 33.1 M 28.6 M 21.4 M 18.1 M 13.6 M 12 M

General and Administrative Expenses

- - - 10.9 M 9.8 M 8.41 M 8.04 M 7.63 M 7.35 M 6.01 M 6.29 M 4.85 M 3.46 M 4.59 M

All numbers in USD currency

Quarterly Income Statement Compugen Ltd.

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

- - - - 86.4 M - 83.9 M - 83.7 M - 82.7 M - 67.9 M - 62 M - 59.8 M - 57.2 M - 51.3 M - 51.1 M - 51.1 M - 50.9 M - 50.6 M - 50.5 M - 50.3 M - 48.5 M - 41 M - 38.4 M - 36.6 M - 36 M - 34.7 M - - -

Revenue

- - - - - 6 M - - 2 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Compugen Ltd. CGEN
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Compugen Ltd. plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Alector Alector
ALEC
$ 2.11 -13.17 % $ 217 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Axsome Therapeutics Axsome Therapeutics
AXSM
$ 163.89 - $ 8.15 B usaUSA
BridgeBio Pharma BridgeBio Pharma
BBIO
$ 64.28 -3.31 % $ 12.3 B usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
BioCardia BioCardia
BCDA
$ 1.37 5.81 % $ 29 M usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
BioLineRx Ltd. BioLineRx Ltd.
BLRX
$ 2.82 -0.35 % $ 908 M israelIsrael
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 59.8 -3.13 % $ 11.5 B usaUSA
Bristol-Myers Squibb Company Bristol-Myers Squibb Company
BMY
$ 62.08 -0.46 % $ 126 B usaUSA
Benitec Biopharma Benitec Biopharma
BNTC
$ 10.93 0.23 % $ 450 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 109.33 -0.82 % $ 27.2 B germanyGermany
Black Diamond Therapeutics Black Diamond Therapeutics
BDTX
$ 2.38 -3.44 % $ 131 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
BioXcel Therapeutics BioXcel Therapeutics
BTAI
$ 1.63 -2.4 % $ 4.13 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Burford Capital Limited Burford Capital Limited
BUR
$ 8.65 2.49 % $ 1.39 B britainBritain
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
BeyondSpring BeyondSpring
BYSI
$ 1.34 -0.87 % $ 54 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Cabaletta Bio Cabaletta Bio
CABA
$ 3.34 0.61 % $ 3.9 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 4.88 2.74 % $ 10.6 B israelIsrael
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Capricor Therapeutics Capricor Therapeutics
CAPR
$ 27.28 -2.32 % $ 731 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 11.67 -3.47 % $ 768 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
C4 Therapeutics C4 Therapeutics
CCCC
$ 3.06 13.3 % $ 254 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
Codexis Codexis
CDXS
$ 0.99 -2.04 % $ 72.7 M usaUSA
Aridis Pharmaceuticals Aridis Pharmaceuticals
ARDS
- 17.91 % $ 11.1 M usaUSA